101 related articles for article (PubMed ID: 1529071)
1. Comparison of a two-stage and three-stage interim-analysis procedure.
Overall JE; Atlas RS
Psychol Rep; 1992 Aug; 71(1):3-14. PubMed ID: 1529071
[TBL] [Abstract][Full Text] [Related]
2. Sample size determination using an interim analysis.
Bristol DR
J Biopharm Stat; 1993 Sep; 3(2):159-66. PubMed ID: 8220401
[TBL] [Abstract][Full Text] [Related]
3. The reassessment of trial perspectives from interim data--a critical view.
Bauer P; Koenig F
Stat Med; 2006 Jan; 25(1):23-36. PubMed ID: 16220517
[TBL] [Abstract][Full Text] [Related]
4. Optimal timing for interim analyses in clinical trials.
Togo K; Iwasaki M
J Biopharm Stat; 2013; 23(5):1067-80. PubMed ID: 23957516
[TBL] [Abstract][Full Text] [Related]
5. Optimal conditional error functions for the control of conditional power.
Brannath W; Bauer P
Biometrics; 2004 Sep; 60(3):715-23. PubMed ID: 15339294
[TBL] [Abstract][Full Text] [Related]
6. Optimal spending functions for asymmetric group sequential designs.
Anderson KM
Biom J; 2007 Jun; 49(3):337-45. PubMed ID: 17623339
[TBL] [Abstract][Full Text] [Related]
7. A comparison of two methods for adaptive interim analyses in clinical trials.
Wassmer G
Biometrics; 1998 Jun; 54(2):696-705. PubMed ID: 9629649
[TBL] [Abstract][Full Text] [Related]
8. Self-designing trial combined with classical group sequential monitoring.
Yin G; Shen Y
J Biopharm Stat; 2005; 15(4):667-75. PubMed ID: 16022171
[TBL] [Abstract][Full Text] [Related]
9. Group sequential tests for bivariate response: interim analyses of clinical trials with both efficacy and safety endpoints.
Jennison C; Turnbull BW
Biometrics; 1993 Sep; 49(3):741-52. PubMed ID: 8241370
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of experiments with adaptive interim analyses.
Bauer P; Köhne K
Biometrics; 1994 Dec; 50(4):1029-41. PubMed ID: 7786985
[TBL] [Abstract][Full Text] [Related]
11. Stopping clinical trials early for benefit: impact on estimation.
Freidlin B; Korn EL
Clin Trials; 2009 Apr; 6(2):119-25. PubMed ID: 19342463
[TBL] [Abstract][Full Text] [Related]
12. Sample size re-estimation in group-sequential response-adaptive clinical trials.
Morgan CC
Stat Med; 2003 Dec; 22(24):3843-57. PubMed ID: 14673942
[TBL] [Abstract][Full Text] [Related]
13. Increasing the sample size when the unblinded interim result is promising.
Chen YH; DeMets DL; Lan KK
Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
[TBL] [Abstract][Full Text] [Related]
14. Multiplicity-adjusted sample size requirements: a strategy to maintain statistical power with Bonferroni adjustments.
Leon AC
J Clin Psychiatry; 2004 Nov; 65(11):1511-4. PubMed ID: 15554764
[TBL] [Abstract][Full Text] [Related]
15. Two-stage designs for dose-finding trials with a biologic endpoint using stepwise tests.
Polley MY; Cheung YK
Biometrics; 2008 Mar; 64(1):232-41. PubMed ID: 17573866
[TBL] [Abstract][Full Text] [Related]
16. MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets.
Siddiqui O; Hung HM; O'Neill R
J Biopharm Stat; 2009; 19(2):227-46. PubMed ID: 19212876
[TBL] [Abstract][Full Text] [Related]
17. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
Lachin JM
Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
[TBL] [Abstract][Full Text] [Related]
18. Design considerations in crossover trials with a single interim analysis and serial patient entry.
Cook RJ; Willan AR
Biometrics; 1996 Jun; 52(2):732-9. PubMed ID: 8672709
[TBL] [Abstract][Full Text] [Related]
19. [Analysis and importance of statistical power and sample size in empirical scientific research].
Klimek KM
Wiad Lek; 2008; 61(7-9):211-5. PubMed ID: 19172834
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the statistical power for multiple tests: a case study.
Yeo A; Qu Y
Pharm Stat; 2009; 8(1):5-11. PubMed ID: 18381588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
